{"entity":{"id":"nct06660654","kind":"trial","name":"A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)","aka":["REJOICE-PanTumor01"],"tldr":"A phase 2 trial of Raludotatug deruxtecan in advanced solid tumours, run by Daiichi Sankyo, active and no longer recruiting.","summary":"A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) is a phase 2 interventional study registered as NCT06660654 by Daiichi Sankyo, with 200 participants enrolled, started 2025-01-06 and due to reach its primary completion in 2027-09-30. Interventions recorded: Raludotatug deruxtecan.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06660654","url":"https://clinicaltrials.gov/study/NCT06660654"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["raludotatug-deruxtecan"],"companies":["daiichi-sankyo","merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06660654","phase":"2","setting":"REJOICE-PanTumor01: A Phase 2, Multicenter, Open-Label, Pan-Tumor Trial to Evaluate Efficacy and Safety of Raludotatug Deruxtecan (R-DXd) in Participants With Advanced/Metastatic Solid Tumors","sponsor":"Daiichi Sankyo","participation":[{"nct":"NCT06660654","source":"https://clinicaltrials.gov/study/NCT06660654","fetchedAt":"2026-10-07T16:54:53.335Z","studySha256":"4599388e8c06724e20c0416c58a6afd84381ac1e02084de20760157ad50c25d6","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-09-24","leadSponsor":"Daiichi Sankyo","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":335,"enrolmentType":"ESTIMATED","siteCount":48,"recruitingSiteCount":0,"countries":["Belgium","China","Denmark","France","Italy","Japan","South Korea","Spain","United States"]}],"started":"2025-01-06","startedType":"actual","enrolled":200,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06660654/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"raludotatug-deruxtecan","kind":"drug","name":"Raludotatug deruxtecan","route":"/drugs/raludotatug-deruxtecan/"}],"company":[{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/"},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}